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AbstrAct
Rapid platelet inhibition plays pivotal role in contemporary treatment of patients presenting with acute 
coronary syndromes. Morphine, the most commonly used analgesic has been proven to impair both 
absorption and onset of action of P2Y12 receptor inhibitors, which can be described as “the morphine 
effect”. Most negative effects of morphine are caused by its undesirable influence on gastrointestinal tract. 
We hypothesized that naloxone, widely administered intravenous opioid reversing drug, may turn out to be 
beneficial if given orally in acute coronary syndrome patients previously treated with morphine. Therefore, 
a phase IV, randomized pilot study was designed so as to evaluate the impact of naloxone administration 
on pharmacokinetics and pharmacodynamics of P2Y12 inhibitor, ticagrelor in unstable angina patients. 
A group of 30 consecutive unstable angina patients treated with ticagrelor and morphine will be randomized 
in a 1:1 ratio into the study arms. To the best of our knowledge, no such approaches to overcome nega-
tive influence of morphine in acute coronary syndrome patients have been described in literature so far.
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Introduction
Contemporary pharmacological treatment of acute 
coronary syndromes (ACS) is based on rapid platelet 
inhibition. According to the latest European Society of 
Cardiology (ESC) Guidelines for the management of 
ACS dual antiplatelet therapy with aspirin and a  po-
tent P2Y12 receptor inhibitor, preferably ticagrelor, is 
a recommended approach. Administration of prasugrel 
is limited to patients whose coronary angiography has 
been completed and constitutes a strong  indication for 
coronary angioplasty [1] 
Throughout the years, patients presenting with 
symptoms of ACS have been administered morphine 
as the first line treatment of pain. Pain alleviation is vital 
not only for humanitarian reasons, but also because of 
the association of pain with the sympathetic activation 
leading to vasospasm and increasing the ischemic 
burden to the heart [2, 3].
Opioid drugs exert their effect through interaction 
with 3 types of transmembrane G-protein-coupled opi-
oid receptors:μ, d and k. The analgetic effect of opioids 
is mainly attributed to interaction with μ opioid recep-
tors in the central nervous system. Activation of opioid 
receptors located in smooth muscles and terminal por-
tions of the peripheral sympathetic and sensory nerves 
of the gastro-intestinal tract depresses gastrointestinal 
motility and secretion through inhibition of neuronal 
release of acetylcholine and VASP [5]. Opioid drugs 
also enhance fluid and electrolyte absorption, mainly 
through activation of the μ and d opioid receptors [5]. As 
a consequence, side-effects such as nausea, vomiting, 
prolonged gastrointestinal passage, constipation and 
abdominal discomfort are evoked.
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The latest ESC guidelines for the management of pa-
tients presenting with ST-segment elevation myocardial 
infarction (STEMI) lowered the class of recommendation 
for morphine administration as its negative influence 
on the pharmacokinetics and pharmacodynamics of 
ticagrelor has recently been discovered [6, 7]. Mor-
phine has been found to intensify the muscle tone of 
the gastrointestinal tract, especially the sphincters, 
which inhibits gastric emptying and weakens intestinal 
peristalsis, which in turn may lead to the impairment of 
intestinal absorption and thus to the decrease of peak 
plasma levels of oral medications [8, 11]. The described 
phenomenon, which can be called “the morphine effect” 
is particularly undesirable in patients treated for STEMI, 
as this population requires immediate platelet inhibition 
to increase the chance of successful therapy [12–14]. 
Optimal methods of overcoming “the morphine effect” 
are yet to be discovered. Several approaches have already 
been described in literature. These methods include 
crushing the tablets of P2Y12 receptor inhibitor, which can 
be useful due to the acceleration of platelets inhibition as 
a consequence of faster drug absorption or co-adminis-
tration of prokinetic drug, e.g. metoclopramide so as to 
speed up the antiplatelet agent absorption [15–18].
The aim of our study is to evaluate the influence of 
naloxone on the pharmakodynamics and pharmakoki-
netics of ticagrelor in patients with unstable angina 
(UA), pretreated with morphine. According to the design 
of the study, the participants will additionally receive 
naloxone – a selective opioid receptor antagonist [19], 
capable of reversing the actions and effects of opioids 
and commonly used in a variety of clinical scenarios 
such as:opioid action reversal in opioid intoxication 
orduring anaesthesia, opioid substitution therapy in 
opioid addiction and reversal of neonatal respiratory 
center depression secondary to opioid administration 
to the mother. In opioid-naive patients, naloxone exerts 
no significant pharmacological effects. The usual route 
of administration of naloxone is parenteral. When ad-
ministered orally or sublingually, naloxone is subjected 
to very intensive first pass metabolism, resulting in final 
bioavailability of as little as 2-3%, making its plasmatic 
concentration barelly detectable [20]. There are litera-
ture reports on successful oral administration of nalox-
one forsevere opioid-related constipation in patients 
with neoplasmatic diseases, without compromising the 
analgetic effect of opioids [2, 3, 21, 22], due to local 
inhibition of intestinal wall opioid receptors [19]. 
Methods
The study was designed as a phase IV, single-cen-
ter, randomized, investigator-initiated, parallel-group, 
open-label, interventional trial. The study protocol 
was approved by the Ethics Committee of Nicolaus 
Copernicus University in Toruń, Ludwik Rydygier Col-
legium Medicum in Bydgoszcz (approval number KB 
339/2016). The investigation site will be the Department 
of Cardiology, Antoni Jurasz University Hospital No. 1 in 
Bydgoszcz, Poland.
This study was designed to evaluate the impact of 
naloxone administration on the pharmacodynamics 
and pharmacokinetics of ticagrelor and its active me-
tabolite AR-C124900XX in patients with UA pectoris 
who received opioid analgesic in the initial phase of 
treatment. All enrolled participants will be assigned ran-
domly in a 1:1 ratio to one of the following 2 groups: 1) 
a group receiving a combination of 180 mg of crushed 
ticagrelor administered orally followed by intravenous 
administration of 5 mg of morphine or 2) a group treated 
with 180 mg of crushed ticagrelor administered orally fol-
lowed by intravenous administration of 5 mg of morphine 
and oral administration of 1 mg of naloxone (Figure 1).
Provision of informed consent is mandatory to 
participate in the study. The main inclusion criterion 
will be the diagnosis of UA pectoris with a mortality risk 
of < 140 points according to the GRACE Score. Other 
inclusion criteria comprise men or non-pregnant women 
aged 18–80 who have given their informed consent to 
undergo coronary angiography and percutaneous coro-
nary intervention if required. The main exclusion criteria 
include recent treatment with any P2Y12 receptor inhib-
itor, anticoagulants, opioid receptor agonists or potent 
CYP3A4 inhibitors within 14 days preceding screening, 
active bleeding, current treatment for malignancy, 
coagulation disorders, past intracranial hemorrhage, 
gastrointestinal hemorrhage within 30 days preceding 
screening, respiratory failure, thrombocytopenia below 
100.000/IU or anemia (hemoglobin concentration below 
10 g/dL). Also, known hypersensitivity to the adminis-
tered substances is a disqualifying factor. A complete list 
of inclusion and exclusion criteria is presented in Table 1.
Sample size calculation
Based on our previous study evaluating the impact 
of metoclopramide administration on pharmacokinetics 
(PK) and pharmacodynamics (PD) of ticagrelor and its 
active metabolite in patients with UA, we assumed that 
a group of 15 participants in each study arm should 
provide sufficient data for further analysis [17, 18, 23].
Endpoints
The primary endpoint is the time needed to achieve 
the maximum plasma concentration of ticagrelor and 
its active metabolite AR-C124900XX. The secondary 
Malwina Aldona Barańska et al., The influence of naloxone on PK/PD of ticagrelor in UA patients
229www.journals.viamedica.pl/medical_research_journal
Figure 1. Trial flowchart. PD - pharmacodynamic PK – pharmacokinetic
Table 1. A complete list of inclusion and exclusion criteria for participation in the study
Inclusion criteria:
— Provision of informed consent prior to any study specific procedures
— Diagnosis of unstable angina
— Male or non-pregnant female, aged 18-80 years 
— Provision of informed consent for angiography and PCI
— GRACE score < 140 pts
Exclusion criteria:
— Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment
— Current treatment with morphine or any opioid “mi” receptor agonist 
— Hypersensitivity to ticagrelor
— Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
— Active bleeding
— History of intracranial hemorrhage
— Recent gastrointestinal bleeding (within 30 days)
— History of coagulation disorders
— Platelet count less than < 100 x 10^3/mcl
— Hemoglobin concentration less than 10.0 g/dl
— History of moderate or severe hepatic impairment
— History of major surgery or severe trauma (within 3 months)
— Risk of bradycardic events as judged by the investigator
— Second or third degree atrioventricular block during screening for eligibility
— History of asthma or severe chronic obstructive pulmonary disease
— Kidney disease requiring  dialysis
— Manifest infection or inflammatory state
— Killip class III or IV during screening for eligibility
— Respiratory failure
— History of severe chronic heart failure (NYHA class III or IV)
— Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, 
nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, 
carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment
— Body weight below 50 kg
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Table 2. A complete list of study endpoints; AUC – area under the plasma concentraton-time curve of ticagrelor; MEA- 
multiplate electrode aggregometry
Primary endpoint of the study
— Time to maximum concentration (tmax) for ticagrelor and AR-C124900XX [Time frame: 6 hours] 
Secondary endpoints of the study
— Maximum ticagrelor and AR-C124900XX concentration [Time frame: 6 hours]
— Area under the plasma concentration-time curve for ticagrelor (AUC 0–6 h) 
[Time frame: pre-dose and 15 min, 30 min, 45 min, 1, 2, 3, 4, 6 hours post dose] 
— Area under the plasma concentration-time curve for AR-C124900XX (AUC 0–6h) 
[Time frame: pre-dose and 15 min, 30 min, 45 min, 1, 2, 3, 4, 6 hours post dose]
— Platelet reactivity assessed by MEA [Time frame: pre-dose and 30 min, 1, 2, 3, 4, 6 hours post dose
endpoints include ticagrelor and AR-C124900XX max-
imum plasma concentration, area under the plasma 
concentration-time curve (AUC) for ticagrelor and AR-
C124900XX (AUC 0–6h) and platelet reactivity assessed 
with Multiple Electrode Aggregometry (MEA) using the 
Multiplate Analyzer prior to and within the time frame of 
six hours following tikagrelor loading dose ( LD). The 
summary of all study endpoints is presented in Table 2.
The blood sample collection as well as pharmaco-
kinetic and pharmacodynamics assessment have been 
previously described [7, 17, 18, 24].
Safety assessment
Only patients with low or intermediate risk of mortal-
ity defined as less than 140 points in the GRACE Score 
will be enrolled in the study. The subjects will be treated 
with a  set of standard medications according to the 
ESC guidelines for the treatment of ACS, including dual 
anti-platelet therapy, ACE-inhibitor, beta-blocker and 
statin. When mandated by clinical deterioration requir-
ing urgent coronary angiography, patients will be ex-
cluded from further participation in the study and will be 
immediately transported directly to cathlab. Morphine 
will be given in a small, single dose after informing the 
patient about potential consequences associated with 
treatment with opioids and after acquisition of informed 
consent from the patient. In case of occurrence of ad-
verse effects after morphine administration, morphine 
reversing agent, i.e. intravenous naloxone will be given. 
Discussion
According to our knowledge, the study is the first 
attempt to evaluate the influence of naloxone co-ad-
ministration on the absorption and antiplatelet action 
of ticagrelor in patients with UA pectoris who received 
morphine. We hope that the results of our research will 
broaden the knowledge regarding optimization of ACS 
treatment and will lead to the development of more 
effective and safer therapeutic approaches for patients 
presenting with myocardial infarction.
The study status
The study is currently recruiting participants. It has 
been registered in clinicaltrials.gov under the identifi-
cation number NCT02939248.
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